Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

By D. Bowtell, S. Böhm, A. A. Ahmed, P. Aspuria, R. Bast, V. Beral, J. Berek, M. Birrer, S. Blagden, M. Bookman and 31 more. Nature Reviews. Cancer, 2015

1,071 citations recorded by the source corpus.

High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.

Subfields: Cancer Research, Oncology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/062b4b524f99a4ceb02601d475f370598ae1e24c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Chunming Cheng
2. Qingya Luo
3. P. Yi
4. Tao Liu
5. Jianhua Yu
6. Jia Yu
7. Lanfang Li
8. Li Li

Citations in the corpus

• The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation (2020, background): “Ovarian cancer is the fifth leading cause of cancer-related death in women worldwide and has the highest mortality rate among gynecological cancers (18).”